Jourilabs, the joint venture of French and Lebanese partners, opened its blood diagnostic reagent manufacturing plant in Addis Ababa as the first of its kind.
While launching the grand opening of the plant at the Sheraton Addis last Friday, Homam Kouwatli (PhD), technical manager/partner of Jourilabs, an affiliation of the Amsahj Group said the decision to bring Jourilabs to Addis was to take part in the promising market and progress being made in the country.
Jourilabs is specialized in the manufacturing of a wide range of clinical chemistry reagents, staining material and standards. "The aim of our laboratories is to achieve the highest possible quality in development," he said. Moving the 20 years of expertise that penetrated the international market a while ago would bring about huge satisfaction for both the company and the country, he added.
According to the founders of Amshaj Manufacturing Plc/Jourilabs, the journey in Eastern Africa has started as the first investment takes place in the vibrant city of Addis Ababa. "We are eager to provide a high--end product that can compete in terms of quality and innovation with top brands in the world," Khaled Challah, Partner said.
They offer high quality products presented in a variety of convenient sizes and volumes to meet the demands of both the small private laboratory and the large hospital laboratory, according to Mebrhatu Meles, state minister of industry. "We have eagerly been looking for such a pharmaceutical laboratory that can hugely boost the country's demand for reagents and equipments," he said. Thus, as the only company producing diagnostic reagents for laboratories, Jourilabs would feel proud, the company officials reiterated.
Items such as Albumin, alkaline, uric acids, phosphates, lactate and iron are among the product lists unveiled by the company. Founded in 2014, Jourilabs has been working with SORCHIM, the leading Swiss enzymes supplier worldwide by the standards of ISO 9001, which makes the company a pioneer in the field. And according to the state minster, the company would be able to increase the national reagent and pharmaceutical production, which is currently limited to 39 percent as the national demand for drugs and medical supplies is met through import (purchase and donation).